Navigation Links
Scioderm's Investigational New Drug (IND) Application for SD-101 for Treatment of Epidermolysis Bullosa (EB) Allowed by the FDA
Date:2/13/2013

RALEIGH, N.C., Feb. 13, 2013 /PRNewswire-iReach/ -- Scioderm announced that the US Food and Drug Administration (FDA) has reviewed and allowed the investigational new drug (IND) application for SD-101 to proceed.  SD-101 is a topical treatment being developed for the treatment of Epidermolysis Bullosa (EB).  The Company plans to initiate a Phase 1 study in the coming months, with initiation of the Phase 2B/3 study in EB patients to occur in the second half of 2013. 

EB is a rare genetic condition that in all of its forms, share the prominent manifestation of extremely fragile skin that blisters or tears with the slightest friction or trauma.  The disease affects not only the skin but also many internal organs and bodily systems.  This particular manifestation has led to EB patients being known as Butterfly children due to the analogous nature of the fragility of the skin to the wings of a butterfly.  As of today there is no cure or effective treatment.  Wound care, pain management and preventative bandaging are the only options available for caregivers, usually the parents or other family members.  The more severe forms of the disease lead to scarring, disfigurement, disability and early death, usually before the age of 30. 

"We are excited to reach this important corporate milestone and to advance this novel therapy in the clinic," stated Robert Ryan , Ph.D., Chairman of the Board and Co-Founder of Scioderm.  "We look forward to continuing our rapid development of this program to treat a disease where there are no current effective therapies.  In addition, we look forward to working closely with the FDA to expedite the continuing clinical testing and regulatory review of SD-101." 

 "I am enthused by the results SD-101 has demonstrated and with the rapid progress Scioderm has achieved in bringing this potential treatment
'/>"/>

SOURCE Scioderm
Copyright©2012 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Sanofi Pasteur Presents Pediatric Data on Investigational Quadrivalent Influenza Vaccine
2. Data from Study of Elderly Depressed Patients are Reported for Investigational Compound Lu AA21004 on Symptoms of Major Depressive Disorder (MDD)
3. Ambit Biosciences and Teva Announce Clearance of an Investigational New Drug (IND) Application for CEP-32496, A Novel BRAF(V600E) Inhibitor
4. Results of Phase II Study of Boehringer Ingelheims Investigational Bronchodilator for COPD Presented at 2012 ATS International Conference
5. Lilly Diabetes Presents Phase II Blood Pressure and Heart Rate Data on Investigational GLP-1 Analog Candidate, Dulaglutide, in Patients with Type 2 Diabetes at the 27th American Society of Hypertension Scientific Meeting
6. Lilly and Boehringer Ingelheim Present Data at the 72nd American Diabetes Association Scientific Sessions® from Phase II Studies Comparing Investigational Novel Basal Insulin to Insulin Glargine
7. Abbott Presents Results of Clinical Studies Evaluating Its Investigational Treatment for Advanced Parkinsons Disease
8. Results For Phase 2b Trial Of Unique Investigational Cell-Based Therapy In Venous Leg Ulcers Published In The Lancet
9. Janssen Biotech Announces Global License and Development Agreement for Investigational Anti-Cancer Agent Daratumumab
10. Clinical Study With Investigational Cream Aims To Help Women Who Experience Painful Sex
11. Omeros Files Investigational New Drug Application for Lead Compound in PDE10 Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/17/2013)... , June 17, 2013 Velplex, LLC announced ... a technology platform that connects buyers and sellers of ... an industry leader. Why? It,s because ... are intimately familiar with the dental industry. They have ... and have diligently worked to negotiate some of the ...
(Date:6/17/2013)... DNAtrix Inc., experts in oncolytic virus development, ... on the company,s lead product, DNX-2401, at the Replicating ... Canada on June 18, 2013. ... leader in the field of oncolytic virus therapy, will ... I TRIAL OF A CONDITIONALLY REPLICATION-COMPETENT ADENOVIRUS DNX-2401 (FORMERLY ...
(Date:6/17/2013)... ST. PAUL, Minn. , June 17, 2013 ... and branding and design agency, Larsen, was awarded the Silver ... Purpose, Repositioning Prime Therapeutics." The award was presented at the ... Awards Ceremony held June 13 at the AXA ... The Silver Anvil, which has been presented ...
Breaking Medicine Technology:TopProdeals.com Rises to Top as Discount Dental Supply Leader 2DNAtrix, Inc. to Present Clinical Study Results for DNX-2401 (Delta 24-RGD), A Conditionally Replication-Competent Adenovirus 2Prime Therapeutics receives prestigious Silver Anvil Award from Public Relations Society of America 2
... March 23 Magellan Biosciences, Inc., an emerging ... has become the first to offer minocycline and telavancin ... and Drug Administration (FDA) has cleared TREK-brand Sensititre MIC ... negative bacterial isolates, as well as telavancin against Gram ...
... and MORRISTOWN, N.J. , March 23 MicroMass Communications, Inc., a world leader in behavioral marketing, ... be supporting the launch of the new center and its mission of promoting the growth of North Carolina ,s ... ... , , ...
Cached Medicine Technology:FDA Clears Three Additional Antimicrobials for Use on TREK Sensititre(R) In Vitro Diagnostic (IVD) MIC Susceptibility Plates: Minocycline and Telavancin Used to Treat MRSA and Other Infections; and Tigecycline, Now Cleared for Streptococcus Pneumoni 2FDA Clears Three Additional Antimicrobials for Use on TREK Sensititre(R) In Vitro Diagnostic (IVD) MIC Susceptibility Plates: Minocycline and Telavancin Used to Treat MRSA and Other Infections; and Tigecycline, Now Cleared for Streptococcus Pneumoni 3FDA Clears Three Additional Antimicrobials for Use on TREK Sensititre(R) In Vitro Diagnostic (IVD) MIC Susceptibility Plates: Minocycline and Telavancin Used to Treat MRSA and Other Infections; and Tigecycline, Now Cleared for Streptococcus Pneumoni 4MicroMass Named Agency of Record for North Carolina Advanced Medical Technologies Center of Innovation 2MicroMass Named Agency of Record for North Carolina Advanced Medical Technologies Center of Innovation 3MicroMass Named Agency of Record for North Carolina Advanced Medical Technologies Center of Innovation 4
(Date:6/18/2013)... Encino, CA (PRWEB) June 18, 2013 ... road to recovery from autism. He receives 40 hours ... services and school shadowing) from the Center for Autism ... with CARD since August, 2008, and has experienced remarkable ... and commenting about his environment. Riley’s personal journey through ...
(Date:6/18/2013)... cells have a much different and more complex ... University of Texas at Dallas have found that exploiting ... lung cancer. , In an article published online May ... Dallas researchers compared the metabolic characteristics of non-small-cell lung ... same patient. , They found that the cancer ...
(Date:6/18/2013)... CLEVELANDA new commercial venture, using technology developed at ... Sciences and Case School of Engineering, has made ... SimuCase allows graduate students and others training to ... Web-based program, reducing stress on the trainee, because ... a real person. , Graduate students studying ...
(Date:6/18/2013)... 2013 More than 1.1 million people in ... according to the Centers for Disease Control and Prevention (CDC). ... In support of National HIV Testing Day on June 27, ... (SSDI) representation, the CDC and other organizations are raising ... CDC reports about 50,000 new HIV infections each year. Along ...
(Date:6/18/2013)... (PRWEB) June 18, 2013 The Elizabeth ... of State and the U.S. President’s Emergency Plan for ... and celebrate significant new milestones in the global effort ... John Kerry announced that as of June 2013, one ... PEPFAR support. Since PEPFAR’s inception in 2003, EGPAF ...
Breaking Medicine News(10 mins):Health News:June's Release of CARD's "Mission Possible: Portraits of Hope" Features Southern California Child and His Remarkable Progress with Intensive Autism Therapy 2Health News:June's Release of CARD's "Mission Possible: Portraits of Hope" Features Southern California Child and His Remarkable Progress with Intensive Autism Therapy 3Health News:UT Dallas study suggests new approach to fight lung cancer 2Health News:UT Dallas study suggests new approach to fight lung cancer 3Health News:SimuCase avatars advance speech-language pathology training 2Health News:Allsup Observes National HIV Testing Day June 27 2Health News:Allsup Observes National HIV Testing Day June 27 3Health News:One Million Babies Born HIV-free Signals Major Milestone in Global Effort to Eliminate Pediatric AIDS 2Health News:One Million Babies Born HIV-free Signals Major Milestone in Global Effort to Eliminate Pediatric AIDS 3
... study has broken the hopes that a combination of ... alternative for preventing strokes //in people with the abnormal ... therapy, of warfarin. ,Canadian researchers have cut ... there is a higher incidence of not only of ...
... Haryana Health Minister Kartar Devi today said government had increased ... education by 50 per cent this fiscal to implement various ... a five-day yoga training camp, being conducted by Swami Ramdev ... necessary to popularise yoga in view of our rich cultural ...
... progressive degeneration of the nerves across the body. Some ... and Kennedy disease. // Researchers have found that ... of the transport of proteins within cells. Hence they ... is unraveled then these diseases could be easily treated. ...
... A 26-year-old woman has delivered identical quadruplets, a rarity ... globally, at a corporate hospital here. // ... girl babies- Aditi, Aakriti, Akshathi, Aapthi, at the Apollo ... her full term, without any medical complications, doctors said., ...
... Pharma major Ranbaxy Laboratories Ltd has entered into a ... Zonisamide Capsules // , which are used for the ... the agreement products would be developed and submitted for ... the products under the the company's label. , ...
... detected here today even as health officials collected blood ... the disease. // ,Officials said a team ... including two children were suffering from jaundice., ,The ... the area as doctors collected blood samples of 20 ...
Cached Medicine News:Health News:Studies Show Combination Drugs As A Poor Substitute For Anti-Coagulants In Stroke 2Health News:Transport of Proteins Unravels the Mystery behind Neurodegenerative Diseases 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: